Pasar al contenido principal

Acciones conjuntas y Unidades mixtas

Acciones conjuntas

Kaertor Foundation

Kærtor Foundation is a private non-profit foundation,registered in the Rexistro de Fundacións de Interese Galego of the Xunta de Galicia, under the protectorate of the Consellería de Economía e Industria. This Foundation counts betweenits patrons to Mabel Loza and Ángel Carracedo, and arises as a continuation and evolution of the Innopharma Project. It is an unprecedented model in the context of Open-innovation and public-private co-development in drug discovery, created to manage the know-how and the results achieved in the Innopharma project and facilitate the reciprocal transfer of knowledge in drug discovery.


The I2D2 program is an incubator for new drugs in an Alliance between the Kaertor Foundation, Janssen and Xunta de Galicia. This program focused on adding value to biomedical research wanted to contribute to the discovery of drugs for diseases without therapeutic solutions, supporting the best biomedical science on the mechanisms of the disease. A de-risking strategy was be applied to drug discovery programs, leaping over in this way the gap towards its industrial application.

Cancer Innova

After the success of I2D2, this new program arises that will allow advance innovative projects and take them to clinical proof of concept in humans within the framework of the Business Factory Medicines. The agents that formed the I2D2, Galician Innovation Agency (GAIN), the company Janssen/Johnson & Johnson and the Kærtor Foundation, now joined by the Science Foundation of Asociación Española Contra el Cáncer and the multinational pharmaceutical company Lilly to unite efforts and share synergies and experiences in favor of a new program in the field of drug discovery focused on the oncology area.

Unidades mixtas

CiMUS - SunRock Biopharma

SunRock is a biotechnology company dedicated to the development of antibodies for the treatment of highly invasive tumors with urgent needs for cancer therapies. Since the approval of the collaboration agreement in 2017, several CiMUS groups have participated in the development of the projects carried out.

CiMUS - Oncostellae

Oncostellae is a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary drug candidates with strong intellectual property and worldwide rights targeting indications in oncology and immunology with high unmet medical need. The collaboration began in 2013 where the BioFarma Group participates, contributing its knowledge in drug Discovery and Characterization of new therapeutic targets.